Omeros (NASDAQ:OMER), founded in 1994 and headquartered in Seattle, Washington, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small-molecule and protein therapeutics. Under the leadership of founder and Chief Executive Officer Gregory A. Demopulos, Omeros has built a platform that integrates structural biology, medicinal chemistry and translational science to address unmet medical needs across multiple therapeutic areas.
Omeros’ first approved product, Omidria™ (phenylephrine and ketorolac injection), is used to maintain pupil size and reduce postoperative pain during cataract surgery and intraocular lens replacement. The company’s clinical pipeline features narsoplimab (OMS721), a monoclonal antibody targeting the lectin complement pathway, in development for rare diseases such as hematopoietic stem cell transplant–associated thrombotic microangiopathy and IgA nephropathy. Additionally, Omeros is advancing PTC299, an orally available small molecule that inhibits viral replication and angiogenesis, in trials for oncology and antiviral indications.
Beyond its lead programs, Omeros employs a discovery engine to identify novel targets and develop proprietary candidates in inflammatory, immunological and central nervous system disorders. The company operates a biologics manufacturing facility in Seattle and collaborates with academic centers and government agencies, including the National Institutes of Health, to accelerate translational research and expand its therapeutic footprint.
Omeros markets products and services principally in North America while preparing for potential regulatory submissions and market access in European and Asian territories. With a seasoned leadership team—including Chief Scientific Officer Derek Neeley and Chief Financial Officer Kathryn Tuley—the company remains focused on advancing late-stage assets toward approval and nurturing early-stage pipelines to deliver new treatment options for patients worldwide.
